Posted on 08 December 2014
Tags: big pharma, Cubist, m& A, Merck & Co
Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days. Read the full story
Posted on 27 August 2014
Tags: big pharma, cancer, Merck & Co, monoclonal antibodies, partnering, Pfizer
Pfizer and Merck & Co announced a clinical trial biotech partnering deal to test Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI) in combination for patients with ALK-positive advanced or metastatic non-small cell lung cancer. Read the full story
Posted on 07 April 2014
Tags: big pharma, Merck, Merck & Co, partnering
Merck and Ferring Pharmaceuticals announced their pharma partnership with the World Health Organization to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Read the full story
Posted on 19 December 2013
Tags: GlaxoSmithKline, GSK, Merck & Co, partnering, pharma licensing
Merck enters into a pharma licensing deal with GSK for evaluating combination therapy for renal cell carcinoma. Read the full story
Posted on 03 December 2013
Tags: asset purchase, big pharma, Forest Labs, Merck & Co, Schizophrenia
Forest Laboratories, big pharma, announced that is acquiring exclusive rights in the United States for Saphris (asenapine). Read the full story
Posted on 07 November 2013
Tags: big pharma, dealtalk, Merck, Merck & Co, Pfizer, spin-out
Merck & Co considering a break off of their animal-health and consumer product division, which could boost their share hold value by $50 billion. Read the full story
Posted on 24 October 2013
Tags: big pharma, licensing, Merck & Co, partnering, pharma partnering
Polyplus-transfection and Merck & Co, announced a global prior use Pharma licensing deals agreement and extended supply agreement for Polyplus-transfection’s polyethylenimine based transfection reagents. Read the full story